LabGenius Ltd announced that it has received £35 million led by new investor Merck Ventures B.V. on May 21, 2024. The transaction included participation from new investors Octopus Ventures Ltd., Recode Health Ventures LLC, LG Corp., returning investors Lux Capital Management, LLC, Atomico Investment Holdings Limited, Kindred Capital LLP and Obvious Ventures, L.P. The company has raised a total funding to date to £58 million. Oliver Hardick of Merck Ventures B.V. and Oliver Sims of Octopus Ventures Ltd. joins the company's board of directors as a part of the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
80,000 KRW | -1.72% | -1.60% | -6.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.87% | 8.98B | |
-18.30% | 180B | |
+1.02% | 166B | |
+3.46% | 155B | |
+4.14% | 99.3B | |
+50.96% | 93.8B | |
+14.41% | 84.11B | |
-3.50% | 73.81B | |
-2.39% | 46.39B | |
-36.10% | 42.58B |
- Stock Market
- Equities
- A003550 Stock
- News LG Corp.
- LabGenius Ltd announced that it has received £35 million in funding from a group of investors